MDGL vs. ALKS, IONS, FOLD, RCKT, GERN, DVAX, LGND, IRWD, YMAB, and GBIO
Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Rocket Pharmaceuticals (RCKT), Geron (GERN), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), Y-mAbs Therapeutics (YMAB), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical preparations" industry.
Alkermes (NASDAQ:ALKS) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.
Alkermes received 238 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 70.84% of users gave Alkermes an outperform vote while only 68.56% of users gave Madrigal Pharmaceuticals an outperform vote.
Alkermes has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Alkermes has a net margin of 21.39% compared to Alkermes' net margin of 0.00%. Madrigal Pharmaceuticals' return on equity of 16.10% beat Alkermes' return on equity.
95.2% of Alkermes shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 4.8% of Alkermes shares are held by company insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Alkermes has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.47, suggesting that its share price is 147% less volatile than the S&P 500.
In the previous week, Madrigal Pharmaceuticals had 5 more articles in the media than Alkermes. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 5 mentions for Alkermes. Alkermes' average media sentiment score of 0.56 beat Madrigal Pharmaceuticals' score of 0.45 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.
Alkermes presently has a consensus target price of $35.38, suggesting a potential upside of 43.51%. Madrigal Pharmaceuticals has a consensus target price of $356.73, suggesting a potential upside of 74.31%. Given Alkermes' stronger consensus rating and higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Alkermes.
Summary
Alkermes beats Madrigal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Madrigal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Madrigal Pharmaceuticals Competitors List
Related Companies and Tools
